DR REDDYS LABORATORIES LTD

Listed Company

RDYCIK 0001135951NYSELarge AcceleratedPharmaceutical PreparationsK7INFY ends Mar 31

Period

FY 2025

Revenue

—

Net Income

$57.24B

Total Assets

$492.99B

Equity

—

Shares Out

834.66M

Op. Cash Flow

—

Business

DR REDDYS LABORATORIES LTD is an integrated global pharmaceutical company that develops, manufactures and commercializes finished pharmaceutical products and active pharmaceutical ingredients. It offers branded and unbranded generics, biosimilars, consumer healthcare and nutraceuticals, APIs and contract discovery, development and manufacturing (CDMO) services, along with proprietary and oncology-focused research through subsidiaries. Its key reportable segments are Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others (including Aurigene Oncology and Proprietary Products). The company sells products across North America, India, Russia and former Soviet countries, Europe and other international markets through sales forces, distributors, wholesalers, hospitals, retail chains and e-commerce channels.

Summary from filing dated 2025-06-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Profit (loss) [abstract]	—	—	—
Analysis of income and expense [abstract]	—	—	—
Revenues	3,580	325,535	279,164
Cost of revenues	1,691	135,107	115,557
Gross profit	1,889	190,428	163,607
Selling, general and administrative expenses	1,137	93,870	77,201
Research and development expenses	256	27,380	22,873
Impairment of non-current assets, net	38	1,693	3
Other income, net	81	4,358	4,199
Total operating expenses	1,350	118,585	95,878
Results from operating activities (A)	539	71,843	67,729
Finance income	84	7,553	5,705
Finance expense	40	2,829	1,711
Finance income, net (B)	44	4,724	3,994
Share of profit of equity accounted investees, net of tax (C)	1	217	147
Profit before tax [(A)+(B)+(C)]	584	76,784	71,870
Tax expense, net	132	19,539	16,186
Profit for the year	452	57,245	55,684
Attributable to:	—	—	—
Equity holders of the parent company	456	56,544	55,684
Non-controlling interests	−4	701	0
Earnings per share attributable to equity holders of the parent company	—	—	—
Basic earnings per share of Rs.1/- each	0.55	67.88	66.93
Diluted earnings per share of Rs.1/- each	0.55	67.78	66.8

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31
Statement of financial position [abstract]	—	—
ASSETS	—	—
Current assets	—	—
Cash and cash equivalents	164	14,654
Other investments	772	43,254
Trade and other receivables	1,079	90,420
Inventories	816	71,085
Derivative financial instruments	2	557
Other current assets	386	30,142
Total current assets	3,219	250,112
Non-current assets	—	—
Property, plant and equipment	1,236	97,761
Goodwill	137	11,810
Other intangible assets	1,120	96,803
Investment in equity accounted investees	60	4,811
Other investments	114	10,391
Deferred tax assets	239	18,508
Tax assets	37	1,821
Other non-current assets	13	972
Total non-current assets	2,956	242,877
Total assets	6,175	492,989
LIABILITIES AND EQUITY	—	—
Current liabilities	—	—
Trade and other payables	356	35,523
Short-term borrowings	630	38,045
Long-term borrowings, current portion	64	857
Provisions	80	6,168
Tax liabilities	46	3,028
Derivative financial instruments	74	1,286
Other current liabilities	537	45,485
Total current liabilities	1,787	130,392
Non-current liabilities	—	—
Long-term borrowings	130	7,864
Deferred tax liabilities	166	14,108
Provisions	1	156
Other non-current liabilities	37	3,303
Total non-current liabilities	334	25,431
Total liabilities	2,121	155,823
Equity	—	—
Share capital	9	834
Treasury shares	19	2,264
Share premium	121	11,133
Share-based payment reserve	18	1,642
Capital redemption reserve	2	173
Retained earnings	3,751	315,793
Other reserves	42	3,979
Other components of equity	94	2,098
Equity attributable to equity holders of the parent company	4,018	333,388
Non-controlling interests	36	3,778
Total equity	4,054	337,166
Total liabilities and equity	6,175	492,989

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Statement of cash flows [abstract]	—	—	—
Cash flows from/(used in) operating activities:	—	—	—
Profit for the year	452	57,245	55,684
Adjustments for:	—	—	—
Tax expense, net	132	19,539	16,186
Fair value changes and profit on sale of financial instruments measured at FVTPL, net	−25	−3,554	−3,149
Depreciation and amortization	220	17,058	14,841
Impairment of non-current assets, net	38	1,693	3
Allowance for credit losses (on trade receivables and other advances)	8	161	275
(Profit)/ Loss on sale/disposal of assets, net	−27	−1,522	−900
Share of profit of equity accounted investees	1	217	147
Unrealized exchange (gain)/loss, net	−6	211	−534
Interest (income)/expense, net	0	−152	567
Inventories write-down	80	5,220	3,563
Equity settled share-based payment expense	3	424	407
Dividend income	0	0	0
Changes in operating assets and liabilities:	—	—	—
Trade and other receivables	−72	−10,283	−8,054
Inventories	−92	−12,753	−18,445
Trade and other payables	30	340	3,460
Other assets and other liabilities, net	11	−7,293	2,857
Cash generated from operations	751	66,421	65,480
Income tax paid, net	144	19,993	20,047
Net cash from operating activities	607	46,428	45,433
Cash flows from/(used in) investing activities:	—	—	—
Purchase of property, plant and equipment	249	27,504	16,403
Proceeds from sale of property, plant and equipment	3	512	1,064
Purchase of other intangible assets	161	6,894	11,032
Proceeds from sale of other intangible assets	15	732	21
Payment for acquisition of businesses	34	53,096	0
Investment in associates	1	317	12
Purchase of other investments (including bank deposits)	498	28,492	41,648
Proceeds from sale of other investments (including bank deposits)	209	53,610	25,944
Dividends received from equity accounted investees	0	0	445
Interest and dividend received	16	3,372	1,338
Net cash used in investing activities	−700	−58,077	−40,283
Cash flows from/(used in) financing activities:	—	—	—
Proceeds from issuance of equity shares (including treasury shares)	4	193	805
Purchase of treasury shares	0	−1,389	0
Proceeds from/(repayment of) short-term borrowings, net	215	24,490	5,493
Proceeds from long-term borrowings (Refer to Note 16 for details)	0	0	3,800
Repayment of long-term borrowings (Refer to Note 16 for details)	0	0	3,800
Proceeds from issuance of equity shares in subsidiary comprising NCI (Refer to Note 35.A for details)	0	7,056	0
Payment of principal portion of lease liabilities (Refer to Note 16 for details)	13	1,294	1,147
Dividend paid	71	6,662	6,648
Interest paid	47	3,483	2,266
Net cash from/(used) in financing activities	88	18,911	−3,763
Net increase/(decrease) in cash and cash equivalents	−5	7,262	1,387
Effect of exchange rate changes on cash and cash equivalents	13	224	−59
Cash and cash equivalents at the end of the year (Refer to Note 6 for details)	—	—	—
Cash and cash equivalents at the end of the year (Refer to Note 6 for details)	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro